The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post-Transplant Complications, Including Sinusoidal Obstruction Syndrome.

IF 2.3 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-09-24 DOI:10.1002/pbc.32073

Kazuki Takahashi, Shinsuke Hirabayashi, Masahiro Ueki, Masataka Hasegawa, Hiroki Ohata, Shunichiro Takezaki, Yukayo Terashita, Yuko Cho, Atsushi Manabe

引用次数: 0

查看原文本刊更多论文

鲁索利替尼治疗家族性吞噬细胞综合征3型婴儿的安全性和有效性：造血细胞移植的桥接疗法和移植后并发症的治疗，包括鼻窦阻塞综合征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.